Patent · US Active

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases

US10150773B2 · kind B2 · utility

2Cited by

0References

8Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Alexandros Vakalopoulos · Hilden, DE
Damian Brockschnieder · Haan, DE
Frank Wunder · Wuppertal, DE
Johannes-Peter Stasch · Wuppertal, DE
Tobias Marquardt · Wuppertal, DE
Lisa DIETZ · Wuppertal, DE
Min Jian Volkhart Li · Velbert, DE

Key dates

Filing date	Feb 2, 2016
Grant date	Dec 11, 2018
Priority date	—
Expiry date	Feb 2, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/05
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.